Updated:
Velocity Clinical Research
Velocity Clinical Research operates as a fully integrated clinical site network, building and acquiring research clinics staffed by principal...
Velocity Clinical Research
Velocity Clinical Research operates as a fully integrated clinical site network, building and acquiring research clinics staffed by principal investigators, coordinators, and recruiters. The firm traces its growth to a roll-up strategy and de novo site launches, concentrating on geographies with high patient-to-trial ratios. Paul Evans, the CEO, has shaped the network through a series of acquisitions that consolidated fragmented, often physician-owned, research practices into a single operational standard across the United States. Velocity's deployment covers Phase I through Phase IV trials, with therapeutic-area concentrations that mirror the outsize demand from sponsoring pharmaceutical and biotechnology companies. Confirmed therapeutic areas include metabolic disease, gastroenterology, central nervous system disorders, and women's health. The network is designed to function as a fixed-cost alternative to reliance on academic medical centers or ad hoc physician practices, with in-house regulatory and data-management backbone that allows study startup in compressed timelines. Sponsors include large-cap vaccine developers and mid-cap biotechs running proof-of-concept protocols. The firm has grown through the COVID-19 era from a small cluster of sites to more than 90 locations across the United States and a growing presence in Europe. Velocity's clinic count expanded notably with its entry into the UK and Central European markets, reflecting a thesis that harmonized site standards solve a persistent pain point for global pivotal trials. August 2023: Velocity opened a new integrated clinical research facility in Texas, expanding its capacity for complex Phase I–II metabolic and liver disease studies embedded within a high-prevalence patient corridor. Velocity's structural differentiator is the depth of its vertical integration: the company employs its own principal investigators as W-2 staff rather than contracting with independent physicians. That employment model aligns investigator incentives with study performance and allows Velocity to standardize protocol execution across dozens of sites simultaneously. In an industry dominated by fragmented investigator sites and multi-layered outsourcing, Velocity offers sponsors a single contract, a single institutional review board, and a single operational playbook for multi-site trials.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Principals
Paul Evans
Chief Executive Officer
G. Paul Evans
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Velocity Clinical Research?
Velocity Clinical Research is a privately held company. As the operating entity, capital allocation and strategic acquisition decisions are led by CEO Paul Evans, who has driven the network's consolidation strategy across the U.S. and Europe. However, as a growth-stage clinical research organization, its growth financing and any associated investment decisions are also influenced by its private equity backers.
Is Velocity Clinical Research a CRO or a site network?
Velocity is a clinical research site network, not a contract research organization (CRO). The critical distinction is that Velocity employs its own principal investigators and owns its clinics, bearing the direct regulatory and operational risk of trial execution, while a CRO typically acts as an outsourced project manager for a sponsor without directly employing site-level investigators or housing patients.
How does Velocity Clinical Research source its trial opportunities?
Velocity secures trial contracts by marketing its integrated network directly to pharmaceutical and biotechnology companies' clinical operations groups, as well as being selected by CROs running sponsor studies. Its model promises faster study startup and reliable patient enrollment by centralizing contracting, regulatory responsibilities, and data management across its owned sites rather than relying on independent physician practices.
What is Velocity Clinical Research's known posture on co-investments alongside external partners?
Velocity Clinical Research is a clinical trial site company, not an investment fund. Its relationships with external partners are operational rather than investment-oriented. The firm does not co-invest in its trial sponsors or partner CROs. Its private equity backers manage the investment posture and capital structure of the entity, not the operating network itself.
What therapeutic areas does Velocity Clinical Research focus on?
Velocity runs trials across multiple therapeutic areas based on the demand of its pharmaceutical and biotech sponsors. Its operational footprint supports gastroenterology, metabolic disease, central nervous system disorders, and women's health among other areas, with its integrated Texas facility specifically targeting complex metabolic and liver disease studies in Phase I and II development.
Where does Velocity Clinical Research operate geographically?
Velocity Clinical Research's primary operational hub is in Durham, North Carolina, with more than 90 integrated clinical sites spread across the United States and a growing presence in Europe. Its geographic strategy concentrates on patient corridors with high population density and under-accessed clinical trial opportunities, including new facility additions in Texas and expansion into the UK and Central Europe.
How does Velocity Clinical Research's employed-investigator model change the clinical trial business?
By employing principal investigators as W-2 staff rather than contracting with independent physicians, Velocity aligns investigator incentives with trial performance metrics such as enrollment speed and data quality. This single-employer model allows the firm to offer pharmaceutical sponsors a single contract and a harmonized operations playbook for multi-site trials, standardizing execution in a way independent sites historically cannot match.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: